ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $18.83.

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus reissued a “hold” rating and issued a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday, April 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th.

Insider Activity at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now directly owns 628,359 shares in the company, valued at $7,006,202.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Jason Lettmann bought 4,400 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the purchase, the chief executive officer now owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the insider now owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The disclosure for this sale can be found here. 50.30% of the stock is owned by insiders.

Institutional Trading of ALX Oncology

A number of institutional investors and hedge funds have recently modified their holdings of ALXO. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in ALX Oncology in the 4th quarter valued at about $28,000. Royal Bank of Canada raised its position in shares of ALX Oncology by 226.6% in the second quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock valued at $30,000 after purchasing an additional 2,776 shares during the period. Legal & General Group Plc raised its position in shares of ALX Oncology by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after purchasing an additional 684 shares during the period. UBS Group AG increased its position in ALX Oncology by 38.7% during the first quarter. UBS Group AG now owns 10,043 shares of the company’s stock worth $45,000 after acquiring an additional 2,801 shares during the period. Finally, SG Americas Securities LLC bought a new stake in ALX Oncology in the 3rd quarter valued at $48,000. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Stock Up 12.4 %

Shares of NASDAQ:ALXO opened at $14.49 on Wednesday. The company has a market cap of $726.67 million, a price-to-earnings ratio of -3.86 and a beta of 1.58. The firm’s 50-day simple moving average is $13.50 and its 200-day simple moving average is $11.84. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05. ALX Oncology has a fifty-two week low of $3.94 and a fifty-two week high of $17.42.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, equities research analysts predict that ALX Oncology will post -3.33 earnings per share for the current year.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.